-
Intellectual Property in
Fashion Industry, WIPO
press release,
December 2, 2005
INSME announcement Archived 2007-09-29 at the
Wayback Machine: WIPO-Italy International...
- dipeptidyl-peptidase I (also
known as
cathepsin C) inhibitor. "Brensocatib -
Insmed". AdisInsight.
Springer Nature Switzerland AG.
Chalmers JD,
Usansky H, Rubino...
-
between Insmed and
Tercica was
settled when the jury
found that
Insmed infringed patents licensed to
Tercica for Increlex. In the settlement,
Insmed agreed...
- Side
effects from
IPLEX are hypoglycemia. IPLEX's
manufacturing company,
Insmed,
after selling its
protein production facility, can no
longer develop proteins...
-
disease product (QIDP) designations. The FDA
granted approval of
Arikayce to
Insmed, Inc. The
safety and
efficacy of
amikacin liposome inhalation suspension...
-
become totally paralyzed. In
January 2007,
INSMED announced that the
Italian Ministry of
Health requested INSMED corporation to make
Iplex available to treat...
-
Regions for
Europe (CPMR)
Danube Commission International Network for SMEs (
INSME)
World Tourism Organization Eurasian Economic Union International Commission...
-
cutaneous squamous cell
carcinoma Amikacin liposome inhalation suspension Insmed mycobacterial lung
disease Emicizumab Genentech hemophilia Lorlatinib Pfizer...
-
Inhibition in COVID-19)
trial is
being provided by
biopharmaceutical company Insmed Incorporated. The
trial is to
start in May 2020 and
researchers plan to...
- 2016-08-05.
Archived from the
original on 2019-05-25.
Retrieved 2019-12-19. "
INSME 10th
Annual Meeting &
Forum Speakers" (PDF). 20
March 2014. "National Agricultural...
